Demand Forecast
Drill-down by category, sub-category, or SKU (p50 + p95 model)
SKU · LAR1698982447001
La Roche-Posay Effaclar Duo+M Soin Triple Correction Anti-Imperfections 40 ml
longtail
3P
CORPS ET VISAGE
OUT OF STOCK
Last 4 weeks demand
2
▼ 81.8% vs prev 4w
Offer Stock
0
no live offers
1P stock
0
no 1P (MARJANEMALL) stock in the latest snapshot
Unit price
MAD 151
avg of last 30 sells · latest 2026-07-30
LAR1698982447001
History (last 52 weeks) and LightGBM p95-quantile forecast for the SKU.
Cutoff: 2026-08-03 · Total forecast: 120 units.
Actual
Realistic forecast
Optimistic
Out of stock
Price history
Weekly qty-weighted average (MAD) of every non-null price/cost column in the OrderBook for this SKU. Click a legend entry to hide/show a line.
Why this forecast?
La Roche-Posay Effaclar Duo+M Soin Triple Correction Anti-Imperfections 40 ml · in the longtail cohort · last 4 weeks 2 units, trending down -81.8% · on-hand 0 units (OUT OF STOCK)
Signals the model saw
- Cohort: longtail (994 days of history, 74 units sold over 52 weeks)
- Volatility (CV): 0.72 — moderate
- Recent trend: last 4w = 2 units · prev 4w = 11 units
- Stockouts (last 13 weeks): none — history is reliable
- Calendar events firing in forecast window: none
Model output
| Realistic forecast — next week | 2.5 units |
| Realistic forecast — next 4 weeks | 12.4 units |
| Realistic forecast — next 3 months | 58.0 units |
| Optimistic — next week | 4.5 units |
| Optimistic — next 4 weeks (reorder target) | 25.8 units |
| Optimistic — next 3 months (quarterly PO target) | 120.0 units |
| Legacy μ/wk (reorder pipeline) | — |
| Revenue exposure — optimistic, 3 months | MAD 18.1K |